You are taking arginine — the molecule your body turns directly into nitric oxide — and yet your blood vessels are not responding the way you expected. Meanwhile, a researcher hands you citrulline, a compound that needs two extra biochemical conversion steps before it becomes arginine, and your plasma arginine levels are now higher than they were on arginine itself. This is not a fluke. It is one of the most important pharmacokinetic lessons in sports nutrition, and once you understand it, the case for combining both compounds becomes clear.

The Problem: Arginine's Journey to Your Bloodstream Is a Minefield

Nitric oxide (NO) is synthesized in endothelial cells by endothelial nitric oxide synthase (eNOS), an enzyme that takes L-arginine as its sole substrate and produces NO plus L-citrulline as a byproduct. The logic of supplementing with L-arginine therefore seems airtight: give eNOS more substrate, get more NO, achieve better vasodilation, blood flow, and performance. Decades of supplement marketing was built on exactly this premise.

There is a serious problem. Oral arginine must pass through your intestinal wall and then through your liver before it reaches systemic circulation — and both compartments are packed with arginase, an enzyme whose job is to break arginine down into ornithine and urea. Tangphao et al. (1999) put a number on this destruction in a rigorous pharmacokinetic study: oral L-arginine at 10 g achieves an absolute bioavailability of approximately 20%. What reaches systemic circulation peaks at around 50 mcg/mL at roughly one hour, then clears rapidly. That means roughly 80% of the arginine you swallow never makes it to the endothelium at all — it is metabolized in the gut wall and liver before it can do anything useful.

This is the pharmacokinetic ceiling that defines oral arginine's limitations as an NO precursor. And it raises an obvious question: what if there were a way to get arginine into the systemic circulation while bypassing the arginase gauntlet entirely?

Citrulline: The Liver Bypass Route

L-citrulline is a non-essential amino acid found in watermelon (citrullus lanatus, hence the name) and produced endogenously as a byproduct of the NOS reaction itself. Unlike arginine, citrulline is not a substrate for arginase — neither intestinal nor hepatic arginase attacks it in any meaningful quantity. This means oral citrulline crosses the gut and passes through the liver largely intact, entering the portal circulation without the massive first-pass extraction that decimates oral arginine.

Once citrulline reaches the kidneys, it meets two enzymes — argininosuccinate synthase (ASS1) and argininosuccinate lyase (ASL) — that convert it back to arginine via the "intestinal-renal axis." This kidney-derived arginine then enters systemic circulation, where it is available for endothelial uptake. Critically, this arginine has never been exposed to hepatic arginase. Per gram ingested, citrulline delivers meaningfully more arginine to the endothelium than oral arginine does — not despite requiring an extra conversion step, but partly because of it.

How the Four Key Mechanisms Work

The Pharmacokinetic Evidence: Citrulline Outperforms Arginine Head-to-Head

The evidence base for citrulline's pharmacokinetic superiority is small but high-quality, with the key comparison study designed specifically to answer this question. Mechanistic reviews have since built on the original pharmacokinetic data to provide a detailed molecular explanation for the findings.

The Arginine Paradox: Why More Substrate Does Not Always Mean More Product

The Liu et al. (2009) finding is worth dwelling on. Ten elite judo athletes took 6 g of arginine daily for three days. Their plasma arginine rose measurably. Their NO metabolites did not move. Their performance did not improve. If arginine simply needed to reach the bloodstream to drive NO synthesis, this result would make no sense — the substrate was clearly there.

The resolution lies in the compartmentalized recycling model. Intracellular arginine in endothelial cells typically sits at 100 to 800 micromolar — far above the Km of eNOS, which is approximately 3 micromolar. In other words, eNOS is not usually substrate-limited by systemic arginine availability in healthy, well-conditioned individuals. The pool of arginine that matters most for NO synthesis is the NOS-proximal pool maintained by ASS1/ASL recycling directly within the endothelial cell. Flooding systemic circulation with more arginine does not necessarily replenish this local pool — it is not directly connected to it.

Citrulline, by contrast, feeds directly into the ASS1/ASL recycling complex inside endothelial cells, replenishing the NOS-proximal arginine pool from within the relevant metabolic compartment. This is why citrulline can improve NO-dependent outcomes in contexts where exogenous arginine cannot. There is also the ADMA factor: if ADMA levels are high (as in populations with cardiovascular disease, diabetes, or metabolic syndrome), eNOS is competitively inhibited regardless of how much arginine is present. Improving the arginine/ADMA ratio — which citrulline does more effectively than arginine, as Schwedhelm et al. (2008) demonstrated — is the relevant intervention.

Why Combining Both Still Makes Pharmacokinetic Sense

If citrulline is pharmacokinetically superior to arginine, why include arginine at all? The answer is temporal. Oral arginine, despite its 20% systemic bioavailability, still produces a rapid and genuine spike in plasma arginine — peaking around one hour post-ingestion. That acute elevation may provide an immediate burst of eNOS substrate during exercise, while citrulline's renal conversion takes longer to generate its arginine contribution, creating a sustained plasma arginine elevation that extends the window of NO precursor availability beyond what the arginine peak alone would provide.

The preclinical evidence from Morita et al. (2014) supports this complementarity: in a rabbit model, the combination of citrulline and arginine produced both faster initial increases in plasma arginine and greater overall increases in cGMP (a downstream marker of NO signaling) than either amino acid alone. This temporal synergy — arginine for the early peak, citrulline for the sustained plateau — is the pharmacokinetic rationale for combination protocols. A meta-analysis by Luo et al. (2025) found that combined citrulline-arginine supplementation produced larger blood pressure reductions (SBP -10.44 mmHg) than either amino acid individually across 15 RCTs — providing indirect clinical support for this combination rationale in vascular populations.

It is important to be honest about the limitations here: the combination synergy evidence in humans is limited and the direct performance data mixed. The strongest evidence remains at the pharmacokinetic and mechanistic level. Whether the combination produces meaningfully greater ergogenic outcomes than citrulline alone in healthy athletes has not been definitively established in human trials.

What This Means in Practice

For athletes and coaches who want to use the NO pathway intelligently, the pharmacokinetic picture has clear practical implications. The relevant question is not just "how much arginine is in my bloodstream?" but "is the NOS-proximal arginine pool inside my endothelial cells adequately supplied?" Citrulline addresses the second question more effectively than arginine does, through both the intestinal-renal axis and the local endothelial recycling loop.

Timing matters because of pharmacokinetics. Arginine absorbs rapidly — peak plasma at roughly one hour — so timing relative to exercise is relevant if you want that acute substrate availability. Citrulline's renal conversion takes longer, providing a more gradual and sustained arginine elevation. Taking both compounds on an empty stomach improves absorption relative to fed-state dosing, because competing amino acids in a protein-containing meal will compete for intestinal transport. This is pharmacokinetic reasoning rather than directly demonstrated human data on fasted versus fed performance outcomes, but it is consistent with how amino acid absorption is understood to work.

The populations who consistently benefit most from NO precursor supplementation are those with some degree of baseline endothelial dysfunction: older adults, individuals with hypertension, people with type 2 diabetes, and those recovering from cardiovascular events. In these populations, ADMA levels tend to be elevated and the endogenous arginine/ADMA ratio compromised — which is precisely the pharmacokinetic vulnerability that citrulline is best positioned to address. In young healthy trained athletes, where the endothelial NOS-proximal pool is well maintained, the pharmacokinetic benefits translate into more modest and less consistent performance improvements.

The Evidence-Based Protocol

What the Research Does Not Yet Tell Us

The pharmacokinetic superiority of citrulline over arginine is well established — this is High-evidence territory. What is less resolved is whether this pharmacokinetic advantage reliably translates into meaningful performance or clinical improvements across all populations. The arginine paradox — why elevated plasma arginine does not reliably produce more NO even when the substrate is clearly present — is only partially explained by the compartmentalized recycling model. The contribution of eNOS uncoupling (where oxidative stress causes the enzyme to produce superoxide instead of NO, regardless of substrate availability) and arginase II competition within endothelial cells remain areas of active investigation. Figueroa et al. (2023) demonstrated that glutathione co-supplementation enhanced citrulline's FMD effect in postmenopausal women, suggesting that reactive oxygen species-mediated NO scavenging may substantially limit the ceiling of what NO precursor supplementation can achieve in high-oxidative-stress populations.

The specific combination of 10 g L-arginine and 3 g L-citrulline administered fasted has not been tested directly in a human clinical trial. The combination synergy evidence rests primarily on an animal study (Morita 2014) and indirect meta-analytic signal from combined supplementation subgroups. The finding that arginine's blood pressure-lowering effect plateaus above 9 g/day and diminishes after 24 days of supplementation (Shiraseb 2022) remains unexplained — compensatory upregulation of arginase is the leading hypothesis, but this has not been confirmed mechanistically in humans. Long-term trials testing whether the ergogenic and cardiovascular effects of combined supplementation persist beyond 4–8 weeks are needed.